WO 2005/075440 PCT/GB2005/000341

Claims

1. A compound of formula (I);

5

10

15

20

wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstitutedC₁₋₆ alkyl;


 R^2 is $(CH_2)_m R^3$ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

 R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted C_{3-8} cycloalkyl group, an unsubstituted or substituted straight or branched C_{1-10} alkyl, an unsubstituted or substituted C_{5-7} cycloalkenyl or R^5 ;

 R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstituted C_{1-6} alkyl, COCH₃, or SO₂Me;

R⁵ is



wherein p is 0, 1 or 2, and X is CH₂, O, S, SO or SO₂;

R⁶ is (C_{3-6}) cycloalkyl, 4- to 7- membered non aromatic heterocyclic group or unsubstituted C_{2-6} alkyl or substituted (C_{1-6}) alkyl;

R⁷ is OH, C₁₋₆alkoxy, NR^{8a}R^{8b}, NHCOR⁹, NHSO₂R⁹, SOqR⁹;

R^{8a} is H or C₁₋₆alkyl;

R^{8b} is H or C₁₋₆alkyl;

30 R^9 is C_{1-6} alkyl;

q is 0, 1 or 2;

and pharmaceutically acceptable derivatives thereof,

wherein R⁶ is not CHxFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3.

- 35 2. A compound as claimed in claim 1 wherein X is CH₂, O or S.
 - 3. A compound as claimed in claim 1 or 2 wherein R^6 is (C_{3-6}) cycloalkyl, 4- to 7- membered non aromatic heterocyclic group or unsubstituted C_{2-6} alkyl.
- 40 4. A compound as claimed in claim 1 wherein compounds of formula (I) are compounds of formula (Ia):

WO 2005/075440 PCT/GB2005/000341

$$R^{3} \longrightarrow H \longrightarrow N \longrightarrow N \longrightarrow (R^{11})_{0}$$

$$R^{3} \longrightarrow N \longrightarrow N \longrightarrow (Ia)$$

wherein:

5

30

 R^3 is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group; R^6 is unsubstituted or substituted C_{2-6} alkyl;

R¹¹ is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy; d is 0, 1, 2 or 3;

and pharmaceutically acceptable derivatives thereof.

- 5. A compound as claimed in any one of claims 1, 2 or 4 wherein R⁶ is either ethyl, substituted ethyl, isopropyl or tert-butyl.
 - 6. A compound as claimed in any preceding claim selected from Example 1 to 5.
- 7. A pharmaceutical composition comprising a compound as claimed in claims 1 to 6 or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.
 - 8. A pharmaceutical composition as claimed in claim 7 further comprising a second theraputic agent.
- 9. A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or (Ia) as claimed in claims 1 to 6 or a pharmaceutically acceptable derivative thereof.
- 10. A method of treating a human or animal subject suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) or formula (Ia) as claimed in claims 1 to 6 or a pharmaceutically acceptable derivative thereof.